Get With The Guidelines-Heart Failure Registry

January 27, 2025 updated by: American Heart Association
Get With The Guidelines-Heart Failure is designed to improve the quality of care in patients hospitalized with heart failure. The program aims to help ensure that eligible patients are initiated on guideline recommended therapies and receive appropriate counseling prior to hospital discharge.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Get With The Guidelines-Heart Failure was initiated in 2005 with over 500 U.S. hospitals participating is designed to improve the quality of care in patients hospitalized with heart failure. The program aims to help ensure that eligible patients are initiated on guideline recommended therapies and receive appropriate counseling prior to hospital discharge.

Peer-reviewed research(with over 35 manuscripts) has demonstrated that through participating in Get With The Guidelines-Heart Failure, hospitals will provide equitable care (regardless of race, ethnicity, age, or gender), the importance of scheduled physician follow-up after heart failure hospital discharge, the value in device-support as necessary for the acute heart failure patient, and many other significant findings.

Achievement measures tracked through Get With The Guidelines-Heart Failure:

  • Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) at discharge
  • Evidence-based specific beta blockers
  • Measure left ventricular function
  • Post-discharge appointment for heart failure patients

Quality Measures tracked through Get With The Guidelines-Heart Failure:

  • Mineralocorticoid receptor antagonist at discharge
  • Aldosterone antagonist at discharge
  • Anticoagulation for atrial fibrillation
  • Hydralazine nitrate at discharge
  • DVT prophylaxis
  • CRT-D or CRT-P placed or prescribed at discharge
  • ICD counseling, or ICD placed or prescribed at discharge
  • Influenza vaccination during flu season
  • Pneumococcal vaccination
  • Follow-up visit within 7 days or less
  • Lab monitoring follow-up
  • SGLT-2 inhibitor at discharge
  • Defect-free care for quadruple therapy medication for patients with heart failure with reduced ejection fraction
  • Direct-acting oral anticoagulant at discharge for non-valvular atrial fibrillation or atrial flutter patients

Additional measures collected by Get With The Guidelines-Heart Failure can be viewed at: http://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_310967.pdf

Study Type

Observational

Enrollment (Estimated)

128026

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 125 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study populations is primary diagnosis or secondary diagnosis of heart failure

Description

Inclusion Criteria:

  • Patients hospitalized with congestive heart failure.

Exclusion Criteria:

  • Patients who do not have congestive heart failure,
  • Patients under age of 18,
  • Patients not admitted as inpatients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30 day readmission rate
Time Frame: 30 days post discharge from hospital
Percent of index encounters where there is a readmission within 30 days
30 days post discharge from hospital
60 day readmission rate
Time Frame: 60 days post discharge from hospital
Percent of index encounters where there is a readmission within 60 days
60 days post discharge from hospital
90 day readmission rate
Time Frame: 90 days post discharge from hospital
Percent of index encounters where there is a readmission within 90 days
90 days post discharge from hospital

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

American Heart Association

Investigators

  • Study Director: Javed Butler, MD, American Heart Association

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2005

Primary Completion (Estimated)

January 1, 2040

Study Completion (Estimated)

January 1, 2040

Study Registration Dates

First Submitted

April 8, 2013

First Submitted That Met QC Criteria

February 25, 2016

First Posted (Estimated)

February 26, 2016

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 27, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GWTG01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on GWTG Heart Failure program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe